Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1040470/000165495420000416/aehr_10q.htm
July 2023
May 2023
May 2023
March 2023
March 2023
March 2023
February 2023
January 2023
January 2023
January 2023
Aehr Test Systems
|
MKR
Investor Relations Inc.
|
Ken
Spink
|
Todd
Kehrli or Jim Byers
|
Chief
Financial Officer
|
Analyst/Investor Contact |
(510)
623-9400 x309
|
(323) 468-2300 |
aehr@mkr-group.com |
AEHR
TEST SYSTEMS AND SUBSIDIARIES
|
|||||
Condensed
Consolidated Statements of Operations
|
|||||
(in thousands,
except per share data)
|
|||||
(unaudited)
|
|||||
|
|
Three
Months Ended
|
Six
Months Ended
|
|||
|
Nov
30,
|
Aug
31,
|
Nov
30,
|
Nov
30,
|
Nov
30,
|
|
2019
|
2019
|
2018
|
2019
|
2018
|
|
|
|
|
|
|
Net
sales
|
$6,874
|
$5,533
|
$5,911
|
$12,407
|
$10,651
|
Cost of
sales
|
3,672
|
3,262
|
3,513
|
6,934
|
6,700
|
Gross
profit
|
3,202
|
2,271
|
2,398
|
5,473
|
3,951
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
Selling,
general and administrative
|
2,157
|
1,808
|
1,977
|
3,965
|
3,856
|
Research
and development
|
795
|
892
|
986
|
1,687
|
2,102
|
Total
operating expenses
|
2,952
|
2,700
|
2,963
|
5,652
|
5,958
|
|
|
|
|
|
|
Income
(loss) from operations
|
250
|
(429)
|
(565)
|
(179)
|
(2,007)
|
|
|
|
|
|
|
Interest income
(expense), net
|
2
|
12
|
(74)
|
14
|
(152)
|
Other income,
net
|
5
|
10
|
29
|
15
|
38
|
|
|
|
|
|
|
Income
(loss) before income tax expense
|
257
|
(407)
|
(610)
|
(150)
|
(2,121)
|
|
|
|
|
|
|
Income tax
expense
|
(6)
|
(6)
|
(19)
|
(12)
|
(23)
|
|
|
|
|
|
|
Net
income (loss)
|
251
|
(413)
|
(629)
|
(162)
|
(2,144)
|
|
|
|
|
|
|
Less: Net income
attributable to the noncontrolling
interest
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
Net income (loss)
attributable to Aehr Test Systems common
shareholders
|
$251
|
$(413)
|
$(629)
|
$(162)
|
$(2,144)
|
|
|
|
|
|
|
Net income (loss) per
share
|
|
|
|
|
|
Basic
|
$0.01
|
$(0.02)
|
$(0.03)
|
$(0.01)
|
$(0.10)
|
Diluted
|
$0.01
|
$(0.02)
|
$(0.03)
|
$(0.01)
|
$(0.10)
|
|
|
|
|
|
|
Shares used in per
share calculations:
|
|
|
|
|
|
Basic
|
22,823
|
22,708
|
22,294
|
22,765
|
22,242
|
Diluted
|
22,912
|
22,708
|
22,294
|
22,765
|
22,242
|
AEHR TEST SYSTEMS AND SUBSIDIARIES
|
|||||
Reconciliation of GAAP and Non-GAAP Results
|
|||||
(in
thousands, except per share data)
|
|||||
(unaudited)
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
Six Months Ended
|
|||
|
Nov 30,
|
Aug 31,
|
Nov 30,
|
Nov 30,
|
Nov 30,
|
|
2019
|
2019
|
2018
|
2019
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net
income (loss)
|
$251
|
$(413)
|
$(629)
|
$(162)
|
$(2,144)
|
Stock-based
compensation expense
|
205
|
199
|
224
|
404
|
480
|
Non-GAAP net
income (loss)
|
$456
|
$(214)
|
$(405)
|
$242
|
$(1,664)
|
|
|
|
|
|
|
GAAP net
income (loss) per diluted share
|
$0.01
|
$(0.02)
|
$(0.03)
|
$(0.01)
|
$(0.10)
|
Non-GAAP net
income (loss) per diluted share
|
$0.02
|
$(0.01)
|
$(0.02)
|
$0.01
|
$(0.07)
|
Shares used in
GAAP diluted shares calculation
|
22,912
|
22,708
|
22,294
|
22,765
|
22,242
|
Shares used in
non-GAAP diluted shares calculation
|
22,912
|
22,708
|
22,294
|
22,846
|
22,242
|
|
|
|
|
|
|
Non-GAAP net income (loss) is a non-GAAP measure and should not be
considered a replacement for GAAP results. Non-GAAP net income
(loss) is a financial measure the Company uses to evaluate the
underlying results and operating performance of the business. The
limitation of this measure is that it excludes items that impact
the Company's current period net income. This limitation is best
addressed by using this measure in combination with net income
(loss) (the most directly comparable GAAP financial measure). These
measures are not in accordance with GAAP and may differ from
non-GAAP methods of accounting and reporting used by other
companies.
We believe these measures enhance investors’ ability to
review the company’s business from the same perspective as
the company’s management and facilitate comparisons of this
period’s results with prior periods.
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
AEHR TEST SYSTEMS AND SUBSIDIARIES
|
||||||||
Condensed Consolidated Balance Sheets
|
||||||||
(in
thousands, except per share data)
|
||||||||
(unaudited)
|
|
November 30,
|
August 31,
|
May 31,
|
|
2019
|
2019
|
2019
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
Cash
and cash equivalents
|
$5,302
|
$5,266
|
$5,428
|
Accounts
receivable, net
|
5,231
|
3,287
|
4,859
|
Inventories
|
9,800
|
9,217
|
9,061
|
Prepaid
expenses and other
|
534
|
523
|
686
|
Total
current assets
|
20,867
|
18,293
|
20,034
|
|
|
|
|
Property
and equipment, net
|
860
|
1,000
|
1,045
|
Operating
lease right-of-use assets
|
2,387
|
2,533
|
-
|
Other
assets
|
186
|
199
|
228
|
Total
assets
|
$24,300
|
$22,025
|
$21,307
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts
payable
|
$2,320
|
$1,742
|
$1,933
|
Accrued
expenses
|
1,596
|
1,577
|
2,034
|
Operating
lease liabilities, short-term
|
619
|
606
|
-
|
Customer
deposits and deferred revenue, short-term
|
1,809
|
615
|
1,545
|
Total
current liabilities
|
6,344
|
4,540
|
5,512
|
|
|
|
|
Deferred
rent
|
-
|
-
|
153
|
Operating
lease liabilities, long-term
|
1,924
|
2,086
|
-
|
Deferred
revenue, long-term
|
64
|
113
|
189
|
Total
liabilities
|
8,332
|
6,739
|
5,854
|
|
|
|
|
Aehr
Test Systems shareholders' equity
|
15,988
|
15,306
|
15,472
|
Noncontrolling
interest
|
(20)
|
(20)
|
(19)
|
Total
shareholders' equity
|
15,968
|
15,286
|
15,453
|
Total
liabilities and shareholders' equity
|
$24,300
|
$22,025
|
$21,307
|
# #
#
|
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1040470/000165495420000416/aehr_10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aehr Test Systems.
Aehr Test Systems's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
Net cash used in operations was also impacted by increases in accounts receivable and inventories of $1.1 million and $935,000, respectively, partially offset by an increase in accounts payable of $302,000 million and an increase in customer deposits and deferred revenue of $231,000.
We anticipate that the existing cash balance together with income from operations, collections of existing accounts receivable, revenue from our existing backlog of products, the sale of inventory on hand, and deposits and down payments against significant orders will be adequate to meet our liquidity requirements for the next 12 months.
The increase in gross profit margin was primarily the result of a change in mix of product sales, and manufacturing efficiencies due to an increase in net sales.
The increase in SG&A expenses was primarily due to an increase in commissions and costs associated with new product introductions.
The increase in SG&A expenses was primarily due to an increase in commissions and costs associated with new product introductions.
Gross profit margin increased to...Read more
Gross profit margin increased to...Read more
The decrease in accrued expenses...Read more
SG&A expenses increased to $2.2...Read more
SG&A expenses increased to $4.0...Read more
The decrease in interest expense...Read more
The decrease in interest expense...Read more
The changes were due to...Read more
Gross profit increased to $3.2...Read more
The increase in accounts receivable...Read more
The increase in accounts receivable...Read more
On an ongoing basis, we...Read more
Net sales increased to $6.9...Read more
Net sales increased to $12.4...Read more
The change in other income,...Read more
The change in other income,...Read more
The increase in inventories and...Read more
The increase in inventories and...Read more
Net sales of the wafer-level...Read more
Net sales of the wafer-level...Read more
Gross profit increased to $5.5...Read more
Factors that could cause or...Read more
The effect of fluctuation in...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Aehr Test Systems provided additional information to their SEC Filing as exhibits
Ticker: AEHR
CIK: 1040470
Form Type: 10-Q Quarterly Report
Accession Number: 0001654954-20-000416
Submitted to the SEC: Tue Jan 14 2020 4:42:51 PM EST
Accepted by the SEC: Tue Jan 14 2020
Period: Saturday, November 30, 2019
Industry: Instruments For Meas And Testing Of Electricity And Elec Signals